AN2 Therapeutics, Inc.

Case Form

Find Out if You Potentially Qualify for a Financial Reward by filling out the form.

The submission of this form does not create an attorney-client relationship.

Investigation Details

Before the market open on February 12, 2024, AN2 Therapeutics announced a pause in Phase 3 enrollment in its seamless Phase 2/3 clinical trial (EBO-301) evaluating epetraborole in treatment-refractory MAC lung disease, pending further data review.

Following this news, shares of AN2 Therapeutics stock over 73% in premarket trading.